Publications To Date


    Filter Publications

    PAGE 3 OF 87 | DISPLAYING 31 - 45 OF 1293 RESULTS

    Kim SH et al. Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary., , Nat Commun, Jan 02, 2020

    Rosell R et al., Novel molecular targets for the treatment of lung cancer., , Curr Opin Oncol, Jan 01, 2020

    Cesano A et al., Status of Immune Oncology: Challenges and Opportunities., , Methods Mol Biol, Jan 01, 2020

    Das K et al., Analysis of Immunological Treatment Effects of Virotherapy in Tumor Tissue., , Methods Mol Biol, Jan 01, 2020

    Cesano A et al., Status of Immune Oncology: Challenges and Opportunities., , Methods Mol Biol, Jan 01, 2020

    Beechem JM et al., High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research., , Methods Mol Biol, Jan 01, 2020

    Leong WI et al., Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses., , Oncotarget, Dec 31, 2019

    Linge A et al., Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC., , Radiother Oncol., Dec 30, 2019

    Nolan MW et al., Pet Dogs with Subclinical Acute Radiodermatitis Experience Widespread Somatosensory Sensitization., , Radiat Res, Dec 26, 2019

    Rozeman EA et al., Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)., , Melanoma Res, Dec 26, 2019

    Zografos E et al., Prognostic role of microRNAs in breast cancer: A systematic review., , Oncotarget, Dec 24, 2019

    Brandão M et al., Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors., , Ann Oncol, Dec 20, 2019

    Kargl J et al., Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC., , JCI Insight, Dec 19, 2019

    Ahern E et al., Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)., , Trials, Dec 19, 2019

    Denker S et al., A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response., , Int J Hematol Oncol, Dec 19, 2019